NASDAQ:AGLE
Aeglea BioTherapeutics, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.aeglea.comipo date
Apr 07, 2016
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 de...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus